1160502-31-7

Basic information

• Product Name: 4-iodo-3-(trifluoromethyl)-1-tritylpyrazolo[5,4-b]pyridine
• Synonyms: 4-iodo-3-(trifluoromethyl)-1-tritylpyrazolo[5,4-b]pyridine
• CAS NO: 1160502-31-7
• Molecular Weight: 555.341
• Mol File: 1160502-31-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-iodo-3-(trifluoromethyl)-1-tritylpyrazolo[5,4-b]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-iodo-3-(trifluoromethyl)-1-tritylpyrazolo[5,4-b]pyridine(1160502-31-7)
• EPA Substance Registry System: 4-iodo-3-(trifluoromethyl)-1-tritylpyrazolo[5,4-b]pyridine(1160502-31-7)

Safety Data

• Hazardous Substances Data: 1160502-31-7(Hazardous Substances Data)

Upstream product

• 113975-22-7 2-fluoro-3-iodopyridine 
• 1160502-29-3 2,2,2-trifluoro-1-(2-fluoro-4-iodopyridin-3-yl)ethanone 
• 1160502-28-2 2,2,2-trifluoro-1-(2-fluoro-4-iodopyridin-3-yl)ethanol 
• 153034-82-3 [(fluoro-2-iodo-4)pyrid-3-yl]-carboxaldehyde 
• 1160502-30-6 4-iodo-3-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridine 
• 76-83-5 trityl chloride 

Downstream Products

• 1160502-32-8 tert-butyl 2-methyl-2-(3-(3-(trifluoromethyl)-1-trityl-1H-pyrazolo[3,4-b]pyridin-4-yl)phenyl)-butylcarbamate 
• 1160502-40-8 tert-butyl 3-(3-(1-cyanocyclopropyl)-5-(3-(trifluoromethyl)-1-trityl-1H-pyrazolo[3,4-b]pyridin-4-yl)phenyl)propylcarbamate 
• 1160502-45-3 tert-butyl N-[[3-[3-[3-(trifluoromethyl)-1-trityl-pyrazolo[3,4-b]pyridin-4-yl]phenyl]oxetan-3-yl]methyl]carbamate 
• 1629023-89-7 C₃₈H₂₇F₃N₄ 
• 1629600-76-5 C₄₀H₂₉F₃N₄O₂ 
• 1620328-23-5 C₃₈H₂₉F₃N₄ 
• 1620328-25-7 C₄₀H₃₁F₃N₄O₂ 
• 1620328-28-0 C₂₁H₁₇F₃N₄O₂ 
• 1620328-45-1 C₃₈H₂₉F₃N₄O 
• 1629023-54-6 C₃₉H₃₁F₃N₄O 
• 1620328-31-5 C₂₀H₁₇F₃N₄O 
• 1160501-79-0 C₁₉H₁₅F₃N₄O 
• 1620328-33-7 C₁₉H₁₃F₃N₄O₂ 
• 1629023-65-9 C₃₈H₂₈F₄N₄ 

Relevant articles and documents

Discovery of selective, orally bioavailable pyrazolopyridine inhibitors of protein kinase cθ (pkcθ) that ameliorate symptoms of experimental autoimmune encephalomyelitis

PKCθ plays an important role in T cell biology and is a validated target for a number of disease states. A series of potent and selective PKCθ inhibitors were designed and synthesized starting from a HTS hit compound. Cell activity, while initially a challenge to achieve, was built into the series by transforming the nitrile unit of the scaffold into a primary amine, the latter predicted to form a new hydrogen bond to Asp508 near the entrance of the ATP binding site of PKCθ. Significant improvements in physiochemical parameters were observed on introduction of an oxetane group proximal to a primary amine leading to compound 22, which demonstrated a reduction of symptoms in a mouse model of multiple sclerosis.

[1H- PYRAZOLO [3, 4-B] PYRIDINE-4-YL] -PHENYLE OR -PYRIDIN-2-YLE DERIVATIVES AS PROTEIN KINASE C-THETA

The present invention relates to compounds of formula (I) and (IA) useful as inhibitors of protein kinase (1a). The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions. (a) : in particular protein kinase C theta, wherein A and A' are independently -N- or -C(R+) -. Ring B is five- or six-membered saturated carbocyclic or heterocyclic R1, R2, R3, R4, R5, R6, R7, x and y are as described herein.